MOTS-c
Mitochondrial-encoded peptide with emerging metabolic-health research.
- Primary research area
- Metabolic / mitochondrial
- Last updated
- Apr 21, 2026
- Reviewed by
- Peptide Examiner editorial team
What it is
MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded by the mitochondrial genome — one of the first mitochondrially-encoded peptides identified in humans. It is a subject of substantial mechanistic research on metabolism, insulin sensitivity, and exercise response, but clinical therapeutic development is early-stage.
Mechanism of action
MOTS-c acts at multiple tissues, but the central proposed mechanism involves activation of AMPK (AMP-activated protein kinase) in skeletal muscle, liver, and adipose tissue, improving insulin sensitivity and glucose disposal. Circulating MOTS-c levels correlate with metabolic health and decline with age; exogenous MOTS-c in animal models reduces insulin resistance and improves exercise performance. It is thought to act as a stress-adaptation signal between mitochondria and the rest of the body.
Research history
Animal model research has been active since the original MOTS-c discovery papers (Lee et al., 2015). Studies demonstrate improvements in glucose tolerance, insulin sensitivity, and exercise endurance with exogenous peptide. Human research has been limited — a handful of early Phase 1 studies on safety and pharmacokinetics. No Phase 2/3 clinical trial program has reported.
Current trial status
Preclinical and early Phase 1 human research. No Phase 2 or Phase 3 trials underway.
Regulatory status
Not FDA approved. FDA Category 2 (September 2023). Feb 2026 HHS proposed removal. Research-use-only sales. Full regulatory timeline →
Controversies and open questions
MOTS-c has genuinely interesting mechanistic biology but the gap between compelling animal data and human therapeutic efficacy is enormous and unproven for this compound. Biohacker marketing often overstates the human evidence.
Further reading
Frequently asked
What makes MOTS-c unusual?
It's one of the first human peptides discovered to be encoded by the mitochondrial genome rather than the nuclear genome. This makes it mechanistically distinct from most peptide therapeutics.
What does the evidence support?
Strong animal evidence for improved insulin sensitivity and exercise endurance via AMPK activation. Very limited human data — a handful of Phase 1 studies. No Phase 2 or Phase 3 trials have reported.
Is it FDA approved?
No. FDA Category 2 (September 2023). February 2026 HHS proposed removal pending FDA review.
Should I trust biohacker claims about MOTS-c?
Treat them skeptically. The gap between animal-model results and human clinical efficacy is typically large for metabolic peptides, and MOTS-c hasn't had the rigorous human testing needed to confirm benefits.